Serum miRNA-126 level and vasculogenic mimicry in patients with hepatitis B hepatocellular carcinoma
SHEN Hong1, CHENG Liya1, ZONG Chunhui2, MA Cheng1, ZHAO Dongyu1
1. Minimally invasive surgery, Characteristic medical center of PAP, Tianjin 300162,China; 2. Institute of acute abdomen, Tianjin Hospital of integrated traditional Chinese and Western Medicine,Tianjin 300100,China
Abstract：Objective To investigate the relationship between miRNA-126 and vasculogenic mimicry (VM) in patients with hepatitis B hepatocellular carcinoma (HCC).Methods A total of 183 patients with hepatitis B related HCC in BCLC stage I-IIa who underwent radical hepatectomy were selected as the research objects from October 2016 to October 2019. At the same time, 183 healthy people were randomly selected as the control group. The expression of miRNA-126 in serum was detected by PCR. Then, HE staining and CD34-PAS double staining were used to analyze the influencing factors of VM positive in HCC patients. The ROC curve for predicting VM was constructed.Results The expression of serum miRNA-126 in HCC patients was lower than that in control group. Among HCC patients, 74 cases were VM positive and 109 cases were VM negative. The result of logistic regression analysis showed that low expression of miRNA-126(P=0.008), tumor size (P=0.001) and increased AFP (P=0.000) were associated with VM. miRNA-126 has a high predictive value for VM positive, AUC=0.869(95%CI:0.815-0.924). Conclusions The expression of miRNA-126 can be used as a noninvasive marker of HCC.
Li Z, Lei Z, Xia Y, et al. Association of preoperative antiviral treatment with incidences of microvascular invasion and early tumor recurrence in hepatitis B virus-related epatocellular carcinoma[J].JAMA Surg,2018,153(10):e182721.
Wei F, Ma C, Zhou T, et al. Exosomes derived from gemcitabine-resistant cells transfer malignant phenotypic traits via delivery of miRNA-222-3p[J].Mol Cancer, 2017,16(1):132.
Sartorius K, Makarova J, Sartorius B, et al. The regulatory role of microRNA in hepatitis-B virus-associated hepatocellular carcinoma (HBV-HCC) Pathogenesis[J].Cells, 2019, 8(12):1504.
[12]
Liao X, Zhu G, Huang R, et al. Identification of potential prognostic microRNA biomarkers for predicting survival in patients with hepatocellular carcinoma[J].Cancer Manag Res, 2018,10,787-803.
[13]
Hu M H, Ma C Y, Wang X M, et al. MicroRNA-126 inhibits tumor proliferation and angiogenesis of hepatocellular carcinoma by down-regulating EGFL7 expression[J].Oncotarget, 2016,7(41):66922-66934.
[14]
Bao J, Yu Y, Chen J, et al. MiR-126 negatively regulates PLK-4 to impact the development of hepatocellular carcinoma via ATR/CHEK1 pathway[J].Cell Death Dis, 2018,9(10):1045.
Du C, Lv Z, Cao L, et al. MiR-126-3p suppresses tumor metastasis and angiogenesis of hepatocellular carcinoma by targeting LRP6 and PIK3R2[J].J Transl Med, 2014,12:259.
2021, Vol. 32 
